Reducing Payer Uncertainty by Predicting Disease Outcomes and Identifying the Right Patient: Fact or Fantasy?

Housekeeping notes

• Turn phones to silent
• Please save questions for final discussion session
  – Microphones for verbal questions
• Taking photographs of slides is allowed
Symposium program

Dr Mark Ratcliffe
Market Access, Pricing and Reimbursement Specialist, Chief Executive Officer, PHMR Ltd., London, UK

Ms Pauline Hernandez
Inflammatory Bowel Disease patient

Dr Panos Kanavos
Associate Professor in International Health Policy in the Department of Health Policy at LSE and Political Science, Deputy Director at LSE Health and Programme Director of the Medical Technology Research Group

Dr Panos Kanavos
Associate Professor in International Health Policy in the Department of Health Policy at LSE and Political Science, Deputy Director at LSE Health and Programme Director of the Medical Technology Research Group

Dr Panos Kanavos
Associate Professor in International Health Policy in the Department of Health Policy at LSE and Political Science, Deputy Director at LSE Health and Programme Director of the Medical Technology Research Group

Dr Panos Kanavos
Associate Professor in International Health Policy in the Department of Health Policy at LSE and Political Science, Deputy Director at LSE Health and Programme Director of the Medical Technology Research Group

Dr Panos Kanavos
Associate Professor in International Health Policy in the Department of Health Policy at LSE and Political Science, Deputy Director at LSE Health and Programme Director of the Medical Technology Research Group

Dr Peter Clark
Chair, NHS England Chemotherapy Clinical Reference Group & National Clinical Lead, Cancer Drug Fund; Former Chair of NICE appraisal committee; Consultant medical oncologist

Dr Nicky Lieberman
Head of Medical Policy, Planning, Research and Innovation Division, Clalit Health Services, Tel Aviv, Israel

Dr Peter Lindgren
Professor of Health Economics at Karolinska Institutet & Managing Director at Institutet för Hälsos och Sjukvårdssekonomi (IHE) - The Swedish institute for Health Economics, Stockholm

Panel discussion

Dr Mark Ratcliffe
Market Access, Pricing and Reimbursement Specialist, Chief Executive Officer, PHMR Ltd., London, UK

Opening & introductions

Patient perspective

Perspective from designers of policies

Payer perspective from the UK

Payer perspective from Israel

Payer perspective from Sweden

Faculty and audience

Closing & thank you note

Reducing Payer Uncertainty by Predicting Disease Outcomes and Identifying the Right Patient: Fact or Fantasy?

A symposium sponsored by Takeda Pharmaceuticals International

Room 112, Centre de Convencions Internacional de Barcelona (CCIB), Barcelona, Spain

Tuesday, November 13, 2018

7:30 AM to 8:30 AM
LIVING WITH IBD – A LONG AND UNCERTAIN JOURNEY

The patient perspective

Ms Pauline Hernandez

DISEASE INTRODUCTION

• Inflammatory bowel disease (IBD) is an umbrella term used to describe disorders that involve chronic inflammation of the digestive tract.

• Two major types of IBD are ulcerative colitis and Crohn’s disease.
  • Ulcerative colitis is limited to the colon or large intestine.
  • Crohn’s disease, can involve any part of the gastrointestinal tract from the mouth to the anus. Most commonly, though, it affects the last part of the small intestine or the colon or both.

• Both ulcerative colitis and Crohn’s disease usually involve severe diarrhea, abdominal pain, fatigue and weight loss.

• IBD can be debilitating and sometimes leads to life-threatening complications. (1)

PATIENT JOURNEY & PERSPECTIVE

• Patients with CD and UC are usually diagnosed in their 20s and 30s. (2)(3)

• The goal of treatment of Crohn’s disease (CD) and ulcerative colitis (UC) is achieving and maintaining symptomatic and endoscopic remission. (4)
  • However, about 23 to 45 percent of people with ulcerative colitis and up to 75 percent of people with Crohn’s disease will eventually require surgery. (5)

• As a patient, a big part of the challenge with IBD is to manage the unpredictable course of the disease with flares & remissions.

1. IBD introduction available at: https://www.mayoclinic.org/diseases-conditions/inflammatory-bowel-disease/symptoms-causes/syc-20353315
IN THE LAST 10 YEARS, GREAT PROGRESS WERE MADE IN THE FIELD OF IBD

LANDSCAPE EVOLUTION

New therapies
New guidelines (clinical, patients, regulatory)
New technologies

Strong recognition from various stakeholders of the need to further develop understanding of the disease, improve clinical outcome, patient education and ensure efficient evidence generation.

Reducing Payer Uncertainty by Predicting Disease Outcomes and Identifying the Right Patient: Fact or Fantasy?

A symposium sponsored by Takeda Pharmaceuticals International
Room 112, Centre de Convencions Internacional de Barcelona (CCIB), Barcelona, Spain
Tuesday, November 13, 2018
7:30 AM to 8:30 AM
Reducing decision uncertainty by combining available data with predictive power to improve access to treatment

Panos Kanavos
London School of Economics
Takeda Symposium, ISPOR, 13 November 2018

Observation 1: What do decision-makers want?

- **Safety** and **Efficacy** are *first* steps to provide evidence for a new treatment;
- **Effectiveness** and **Efficiency** need to be proven;
- **Affordability** is increasingly a requirement for coverage and may result in access restrictions
- Significant degree of **uncertainty** in value assessment;

<table>
<thead>
<tr>
<th>Safety</th>
<th>Efficacy</th>
<th>Effectiveness</th>
<th>Efficiency</th>
<th>Affordability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measure of adverse effects</td>
<td>Measure of effect under ideal conditions</td>
<td>Measure of effect under “real life” conditions</td>
<td>Relationships between costs and benefits</td>
<td>Whether health system can pay for it</td>
</tr>
</tbody>
</table>

Competence of regulatory agencies

Competence of HTA agencies/reimbursement committees

- Efficacy does not imply effectiveness and effectiveness does not imply efficiency
- Safety and efficacy are the competence of regulators, effectiveness, efficiency and affordability are the competence of payers/insurers
- Use of HTA to assess value for money and affordability; increasing use of RWE now/in future
**Observation 2: New approaches to licensing of new therapies**

- An increasing number of new therapies are approved (conditionally) with early stage data
- Two steps in the demonstration of safety and efficacy
  - *Experimental phase*: effect size studied in conventional phase 2 studies → CMA
  - *Observational phase*: treated patients are followed to assess whether the promise shown is fulfilled
  - If initial promise is fulfilled → full MA

**Observation 3: Increased use of managed entry to mitigate uncertainty**

- Volume- or expenditure-based rebates aim to provide budgetary predictability and limit budget impact
- Outcomes-based contracts are used to address clinical uncertainty about health outcomes for new products
- Risk-sharing can include shared risk of potential overspend based on pre-defined budget, dose caps, and response rates

---

**Select MEA/contracting mechanism (resulting in a rebate / discount “R/D”)**

- Simple financial R/D on a drug’s list price
- Price-volume / utilization controls / usage patterns / pay-back
- Free product or in-kind contribution based on utilization
- Bundling
- Research funding
- Health outcomes, patient use, other risk sharing
- Economic investment
Towards a new paradigm: using predictive algorithms and combining data from RCTs and RWE to improve treatment pathways and access to treatment

Scientific landscape around predictive power in decision making or HEOR

• What is the potential for using predictive tools and/or methodologies in decision making?
  • Significant potential to improve the quality of care delivered to patients
  • Use of predictive algorithms and data analytics is very limited in most settings
  • There are some predictive algorithms tested in the UK, Sweden, Israel

• Areas where predictive tools/methodologies are already used in decision making
  • Over the past 5 years, tools to predict treatment outcomes have been developed in the following disease areas: oncology, CVD, liver disease, kidney disease (among others)
  • Methods have been developed to predict the following treatment outcomes:
    • Surgery and transplant success
    • Neurological effects
    • Occurrence of infections
    • Survival
    • Treatment efficacy/failure
  • Several studies have examined the use of these tools for predicting treatment outcomes in elderly patients
  • Scoring systems are commonly used, including bio-marker based scoring systems
Foundational pieces of evidence and their roles

- Randomised controlled trials (RCT) versus real world evidence (RWE) — How these can be integrated to help the algorithms and decision making
- Meaningful data for payers and patients and how can it be used for decision making and future risk sharing agreements
- Collaboration between key stakeholders is likely to fill in such data gaps in disease areas such as inflammatory bowel disease (IBD)

Important considerations

<table>
<thead>
<tr>
<th>Role of RWE</th>
<th>Role of HE modelling</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impact HTA 2020</td>
<td>Role of HE modelling in decision making</td>
</tr>
<tr>
<td>BD4BO initiative</td>
<td>Potential for predictive power to evolve</td>
</tr>
<tr>
<td>Prospective monitoring of predicted outcome</td>
<td>Risk sharing partnerships</td>
</tr>
<tr>
<td>The role of PRO as a validator of patient relevance</td>
<td>Role of academia</td>
</tr>
</tbody>
</table>

Other considerations
- The importance of iteration, as we get more data the predictions can improve (machine learning capabilities?)
- The importance of the endpoint for which more data exist vs. the endpoint of interest to decision makers, and how to integrate data that map from one to the other
Impact HTA, WP6: Methodological guidance on the analysis and interpretation of non-randomised studies to inform health economic evaluation - activities

<table>
<thead>
<tr>
<th>Meta-epidemiological review</th>
<th>Case studies</th>
<th>Workshops</th>
</tr>
</thead>
<tbody>
<tr>
<td>✓ Protocol registered on PROSPERO</td>
<td>✓ Identified candidate drugs for NICE case study</td>
<td>✓ 1st workshop planned: aims to raise awareness, provide input for WP6 work on and easy uptake of methodological guidance, and identify gaps not addressed by WP6</td>
</tr>
<tr>
<td>✓ Database searches conducted to identify clinical topics with both RCTs and non-randomized studies</td>
<td>✓ Defined roles for WP partners: potential to leverage diversity of jurisdictions and approaches to HTA through case studies in WP countries</td>
<td>✓ Participants confirmed</td>
</tr>
<tr>
<td>✓ Ongoing: screening through 11,000+ records</td>
<td>✓ Case study work to start in late 2019</td>
<td>✓ Workshop to take place on 19 November 2018</td>
</tr>
</tbody>
</table>

How can this approach be put into practice and be developed into a multi-stakeholder partnership?

- Local data capacity and usage within General Data Protection Regulation (GDPR)
- Willingness to risk share with pharma (difficulty of countries willing countries than findings those that a more resistant, e.g. Sweden?)
- Incorporation of predictive power into guidelines (Rightcare in UK)
  - Managing ongoing uncertainty?
- Research on the topic and further academic guidance on how to link the dots (academia)
  - Including modelling
- Patient reported outcome (PRO) and definition of meaningful patient/payer research targets for modifying long-term disease (patient/all)
  - Will PROs be used to implement this in practice. Should they? If they are, is there a need to make the link between PROs and these patient/payer research targets? Will this approach require a change in mindset from decision makers?
How can this approach be put into practice and be developed into a multi-stakeholder partnership?

• Shared definition of the outcomes of interest?

• Quantification of the outcomes’ impact on healthcare resources and use?

• Ability to track patients, share back outcome data?

• Willingness to plan and budget over a long-term horizon rather than year to year

• Shift mindset to broader disease control of a population rather than patient to patient

Reducing Payer Uncertainty by Predicting Disease Outcomes and Identifying the Right Patient: Fact or Fantasy?
UK payer perspective

Dr Peter Clark, MA, MD, FRCP
Chair, NHS England Chemotherapy Clinical Reference Group & National Clinical Lead, Cancer Drug Fund; Former Chair of NICE appraisal committee; Consultant medical oncologist

English payer perspective on predictive disease outcomes in oncology

• NICE now appraises drugs prior to granting of marketing authorisation i.e. the only data for HTA of a new drug/indication is derived from clinical trial(s). NICE could consider the use of predictive measure in its HTA but this would be based on the clinical trial data as there would be no real world evidence at time of licensing
• Marketing authorisations restrict use of some drugs to specific populations of patients e.g. HER-2, RAS, EGFR, ALK, ROS-1, PD-L1
• Few surrogate markers for robust prediction of meaningful benefit for overall survival and QOL in individuals (e.g. some leukaemias) yet most new drugs/indications licensed on other measures: progression free survival, response rate, pathological complete response rate
• NHS England translates NICE recommendations into directing how a cancer drug is to be used in practice e.g. place in the treatment pathway including previous therapies if relevant, e.g. specific populations defined by disease and patient characteristics such as patient performance status, e.g. treatment duration
Potential use of predictive measures of disease outcomes in oncology

• Robust, validated, reliable and clinically relevant measure
• Easy to measure and at a time that is relatively early in the treatment
• Clear threshold for subsequent action: stopping of treatment or activation of differential reimbursement mechanism
• Collection of data: by clinicians, hospitals, commissioners and its burden, subsequent analysis and challenge
• Practical implementability in the real world
• Limitation of pricing models in England
• Outcome-based pricing being piloted in the Cancer Drugs Fund but not of predictive measures (time for that is in the NICE HTA)

Reducing Payer Uncertainty by Predicting Disease Outcomes and Identifying the Right Patient: Fact or Fantasy?
Value in health care systems & new thoughts in treatment of IBD and autoimmune diseases

Nicky Liebermann M.D
Clalit - ISRAEL

Israel

• Reimbursement
  ✓ All drugs according to established and approved guidelines
  ✓ Combinations in special clinical cases, according to a “special cases” committee.
  ✓ Clalit and the GI specialists are interested in innovation = changing the existing protocols

• Future
  ✓ Big data analysis
  ✓ Omics analysis
  ✓ Patient disease journey & diary
  ✓ Use for Microbiome ??
Value for all

• Identifying “benign” patients and “stormy” ones
• Treating “benign” patients according to existing guidelines.
• Treating “stormy” patients with biologicals in 1st line.
• Treating to “biological remission” and “dim treatment”
• Follow up and prevent exacerbations

Win for patients; win for payers; win for industry

Reducing Payer Uncertainty by Predicting Disease Outcomes and Identifying the Right Patient: Fact or Fantasy?

A symposium sponsored by Takeda Pharmaceuticals International
Room 112, Centre de Convencions Internacional de Barcelona (CCIB), Barcelona, Spain
Tuesday, November 13, 2018
7:30 AM to 8:30 AM
Predictive modelling within the standard reimbursement framework?

- Limiting coverage is a standard tool used by TLV
  - Specific treatment line
  - Specific subpopulation (high risk, specific disease characteristics)
  - In specific treatment combinations
- Reimbursement conditional on use of a predictive algorithm not fundamentally different
- Data needed on the effectiveness in the population to which the reimbursement is limited
- Key question from TLV: How can we be sure that the criteria for reimbursement are met in practice?
What about more sophisticated contracts?

- No outcomes based agreements in MEA at the national level (from 3-party deliberations between manufacturers, TLV and regional payers)
- Key issues payers raise:
  - Fear of administrative burden (particularly in smaller county councils)
  - Fragmented IT, limitations on follow-up on disease specifics at the national level
  - Fear of adding additional burden on physicians
  - Does the cost of implementing an agreement make sense vs. for instance a simpler rebate scheme?
- Separate agreement with more interested regional payers may be more feasible

Questions to the panellists and audience

- National versus regional/local challenges and solutions for the use of predictive techniques
- Institutional requirements that need to be addressed for this to be a success (e.g. agreement on key endpoints, use of real-world data (RWD), approach to decision making under uncertainty)
- Progress so far versus potential future implementation and success areas
- How to address institutional/systemic barriers to the implementation of these approaches
- IBD versus other therapeutic areas (i.e. from the particular problem (IBD) to the general (how the solutions can be used beyond IBD) versus oncology
- How the use of predictive techniques differs from or can be integrated with other patient selection techniques such as biomarkers to ensure more targeted healthcare
Thank you.